Aditxt Inc. (NASDAQ: ADTX) announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first site, Dedicated to Women OB/GYN in Dover, Delaware, has begun enrollment.
This development represents a significant advancement in women's healthcare, as endometriosis affects approximately 10% of women worldwide and currently requires invasive surgical procedures for definitive diagnosis. The condition, where tissue similar to the uterine lining grows outside the uterus, often takes 7-10 years to diagnose using current methods, leading to prolonged suffering and potential fertility complications for millions of women.
Pearsanta President Chris Mitton stated that this milestone supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis. Early diagnosis is crucial for effective management of the condition, which can cause chronic pelvic pain, painful periods, and infertility. The blood-based test could revolutionize diagnostic protocols by providing a simpler, more accessible screening method that doesn't require surgical intervention.
The clinical study's design comparing MET directly against the laparoscopic gold standard ensures rigorous validation of the test's accuracy and reliability. If successful, this diagnostic approach could transform standard care practices in gynecology and women's health. The study information is available through the company's newsroom at https://ibn.fm/ADTX, while additional details about the test and study can be found at https://ibn.fm/WiIhM.
For the healthcare industry, successful validation of this blood-based test could lead to reduced healthcare costs by minimizing unnecessary surgical procedures and enabling earlier intervention. The test's non-invasive nature could also increase screening accessibility in underserved communities and reduce diagnostic delays that currently plague endometriosis care. This innovation aligns with broader trends in precision medicine and liquid biopsy technologies that are transforming diagnostic approaches across multiple medical specialties.
The potential impact extends beyond individual patient care to public health systems worldwide. Earlier diagnosis could help reduce the economic burden of endometriosis, estimated to cost billions annually in healthcare expenses and lost productivity. As the study progresses through its enrollment targets, the medical community will be watching closely for results that could establish a new standard in women's health diagnostics and improve quality of life for millions affected by this chronic condition.
